id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-303577-2gxo5mft	Flaczyk, Adam	Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations	2020-09-16		.txt	text/plain	5705	259	30	We review seven major societal recommendations and guidelines addressing the management of coagulopathy in COVID-19 patients: the Centers for Disease Control and Prevention (CDC) [6] , International Society on Thrombosis and Haemostasis interim guidance (ISTH-IG) [7] , American Society of Hematology (ASH) [8, 9] , American College of Chest Physicians (ACCP) [10] , Scientific and Standardization Committee of ISTH (SCC-ISTH) [11] , Anticoagulation Forum (ACF) [12] , and American College of Cardiology (ACC) [13] . Tables 1, 2, 3, 4, 5, 6, and 7 highlights six major societal recommendations and guidelines on the management of CAC focusing on several critical care issues: (1) laboratory testing for risk stratification and triage, (2) use of biomarkers to guide anticoagulation, (3) proposals for alterations of standard prophylactic VTE anticoagulation regimens for the prevention of thrombotic complications, (4) examination of available medications preferred for anticoagulation, (5) considerations for initiation of therapeutic anticoagulation, (6) indications for thrombolytic therapy, (7) decision-making regarding withholding anticoagulation treatment, (8) use of mechanical thromboprophylaxis, (9) monitoring of anticoagulation, (10) duration of therapeutic anticoagulation, (11) necessity of anticoagulation at discharge, and (12) treatment of active bleeding.	./cache/cord-303577-2gxo5mft.txt	./txt/cord-303577-2gxo5mft.txt